'''Naluzotan''' ([[International Nonproprietary Name|INN]], [[United States Adopted Name|USAN]]; '''PRX-00023''') is a [[serotonergic]] [[drug]] of the [[phenylpiperazine]] class that was under investigation by [[EPIX Pharmaceuticals Inc]] for the treatment of [[generalized anxiety disorder]] and [[major depressive disorder]].<ref name="pmid17263189" /><ref name="pmid18344738">{{cite journal | vauthors = Rickels K, Mathew S, Banov MD, Zimbroff DL, Oshana S, Parsons EC, Donahue SR, Kauffman M, Iyer GR, Reinhard JF | title = Effects of PRX-00023, a novel, selective serotonin 1A receptor agonist on measures of anxiety and depression in generalized anxiety disorder: results of a double-blind, placebo-controlled trial | journal = J Clin Psychopharmacol. | volume = 28 | issue = 2 | pages = 235–239 | year = 2008 | pmid = 18344738 | doi = 10.1097/JCP.0b013e31816774de }}</ref> It acts as a [[binding selectivity|selective]] and [[potency (pharmacology)|potent]] [[5-HT1A|5-HT<sub>1A</sub>]] [[receptor (biochemistry)|receptor]] [[partial agonist]],<ref name="pmid18344738"/><ref name="pmid16722631">{{cite journal | vauthors = Becker OM, Dhanoa DS, Marantz Y, Chen D, Shacham S, Cheruku S, Heifetz A, Mohanty P, Fichman M, Sharadendu A, Nudelman R, Kauffman M, Noiman S | title = An integrated in silico 3D model-driven discovery of a novel, potent, and selective amidosulfonamide 5-HT1A agonist (PRX-00023) for the treatment of anxiety and depression | journal = J Med Chem. | volume = 49 | issue = 11 | pages = 3116–3135 | year = 2006 | pmid = 16722631 | doi = 10.1021/jm0508641 }}</ref> readily stimulating [[prolactin]] responses,<ref name="pmid17495280">{{cite journal | vauthors = Iyer GR, Reinhard JF, Oshana S, Kauffman M, Donahue S | title = Tolerability, pharmacokinetics, and neuroendocrine effects of PRX-00023, a novel 5-HT1A agonist, in healthy subjects. | journal = J Clin Pharmacol. | volume = 47 | issue = 7 | pages = 817–824 | year = 2007 | pmid = 17495280 | doi = 10.1177/0091270007300953 }}</ref> though it has also been found to bind to and activate the [[sigma receptor|σ receptor]].<ref name="isbn0-470-51979-7">{{cite book | author = Prof John Kelly | title = Principles of CNS Drug Development: From Test Tube to Patient | publisher = Wiley | location = New York | year = 2010 | pages = | isbn = 0-470-51979-7 | oclc = | doi = | url = https://books.google.com/books?id=pfY3xcsu6EsC&lpg=PA265&dq=adatanserin&pg=PA265#v=onepage&q=PRX-00023}}</ref> Naluzotan was well tolerated in [[clinical trial]]s,<ref name="pmid17495280" /> with more patients in the control group dropping out due to [[adverse effect]]s than in the active group in one study.<ref name="pmid18344738" /> The most frequently reported side effect was [[headache]] in 15% of patients (compared to 10% for placebo).<ref name="pmid18344738" /> In addition, naluzotan demonstrated significant [[antidepressant]] and [[anxiolytic]] effects as per the [[Hamilton Rating Scale for Depression|HAM-D]] and [[Montgomery-Asberg Depression Rating Scale|MADRS]] and the [[Hamilton Rating Scale for Anxiety|HAM-A]], respectively, in some trials,<ref name="pmid18344738" /> but in others it did not.<ref name="pmid18840371">{{cite journal | vauthors = Mathew SJ, Garakani A, Reinhard JF, Oshana S, Donahue S | title = Short-term tolerability of a nonazapirone selective serotonin 1A agonist in adults with generalized anxiety disorder: a 28-day, open-label study | journal = Clin Ther. | volume = 30 | issue = 9 | pages = 1658–1666 | year = 2008 | pmid = 18840371 | doi = 10.1016/j.clinthera.2008.09.006 }}</ref><ref name="pmid19715445">{{cite journal | vauthors = Kirchhoff VD, Nguyen HT, Soczynska JK, Woldeyohannes H, McIntyre RS | title = Discontinued psychiatric drugs in 2008 | journal = Expert Opinion on Investigational Drugs | volume = 18 | issue = 10 | pages = 1431–43 | date = October 2009 | pmid = 19715445 | doi = 10.1517/13543780903184591 | url = http://informahealthcare.com/doi/abs/10.1517/13543780903184591 }}</ref> In the end it was not found to be significantly superior enough to [[placebo]] and development was stopped.<ref name="pmid19715445" />
